Abstract
BACKGROUND: New treatment methods of castration-resistant prostate cancer with radionuclide therapy are needed. They will optimize personalized strategy for radionuclide therapy of metastatic castrate-resistant prostate cancer using low molecular weight ligands to prostate-specific membrane antigen (PSMA) labeled with lutetium-177.
AIM: To define the long-term effects and effectiveness of the treatment experimental animals with PET imaging to refine the research strategy.
METHODS: The study was performed in nu/nu male mice with PSMA-expressing 22Rv1 prostate cancer xenografts. Positron emission computed tomography with 18F-PSMA-1007 was used to confirm the tumor regrowth after a single therapeutic dose of [177Lu]Lu-PSMA-IT.
RESULTS: Positron emission tomography imaging with 18F-PSMA-1007 showed the possibility of prolonged 22Rv1 tumor regrowth after a single injection of 9.2 MBq of [177Lu]Lu-PSMA-IT, which is equivalent to minimal human therapeutic dose (28.6 MBq/kg).
CONCLUSIONS: The study confirmed the short period of the observed therapeutic effect after a single injection of 9.2 MBq of [177Lu]Lu-PSMA-IT. The tumor regrowth in 2.5 months after the reduction of 22Rv1 xenografts to a non-palpable state was confirmed by positron emission computed tomography with 18F-PSMA-1007. These results confirm the need to study the frequency of repeated administrations of radiopharmaceuticals based on ligands to PSMA labeled with lutetium-177 to achieve a stable therapeutic effect in cases where a single dose reduction is necessary.
Reference25 articles.
1. A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer
2. Prostate Cancer with Bone Metastases: Addressing Chronic Pain from the Perspective of the Radiation Oncology Nurse Practitioner
3. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine. [cited 2023 Oct 1]. Available from: https://clinicaltrials.gov/ct2/results?cond=&term=177Lu+PSMA&cntry=&state=&city=&dist=&Search=Search
4. Committee for Medicinal Products for Human Use (CHMP). Assessment report Pluvicto. 2022 Oct. EMA/871459/2022.